Sabbioni G, Hartley R, Henschler D, Höllrigl-Rosta A, Koeber R, Schneider S
Walther-Straub-Institut für Pharmakologie und Toxikologie, Ludwig-Maximilians-Universität München, Nussbaumstrasse 26, D-80336 München, Germany.
Chem Res Toxicol. 2000 Feb;13(2):82-9. doi: 10.1021/tx990096e.
4,4'-Methylenediphenyl diisocyanate (MDI) is the most important of the isocyanates used as intermediates in the chemical industry. Among the main types of damage after exposure to low levels of MDI are lung sensitization and asthma. Protein adducts of MDI might be involved in the etiology of sensitization reactions. It is therefore necessary to have sensitive and specific methods for monitoring the isocyanate exposure of workers. To date, urine metabolites or protein adducts have been used as biomarkers in workers exposed to MDI. However, with these methods it is not possible to determine if the biomarkers result from exposure to MDI or to the parent aromatic amine 4,4'-methylenedianiline (MDA). This work presents a procedure for quantitating isocyanate-specific hemoglobin adducts. Blood proteins are used as markers of exposure and possibly as markers of dose size for the modifications of macromolecules in the target organs where the disease develops. For the quantitation of hemoglobin adducts, N(1)-[4-(4-isocyanatobenzyl)phenyl]acetamide (AcMDI) was reacted with the tripeptide valyl-glycyl-glycine and with valine yielding N-[4-(4-acetylaminobenzyl)phenyl]carbamoyl]valyl-glycyl-glycine and N-[4-[4-(acetylaminobenzyl)phenyl]carbamoyl]valine, respectively. N-[4-[4-(Acetylamino-3,5-dideuteriobenzyl)-2, 6-dideuteriophenyl]carbamoyl]valine was synthesized from valine, as was N(1)-[4-(4-isocyanato-3,5-dideuteriobenzyl)-2, 6-dideuteriophenyl]acetamide, for use as an internal standard. These adducts were cleaved in 2 M HCl to yield the corresponding hydantoins, 3-[4-(4-aminobenzyl)phenyl]-5-isopropyl-1, 3-imidazoline-2,4-dione (MDA-Val-Hyd) and 3-[4-(4-amino-3, 5-dideuteriobenzyl)-2,6-dideuteriophenyl]-5-isopropyl-1, 3-imidazoline-2,4-dione, respectively. In globin of rats exposed to MDI, MDA-Val-Hyd could be found in a dose-dependent manner. The adduct was identified by HPLC/MS/MS and quantified by GC/MS after derivatization with heptafluorobutyric anhydride. The amount of MDA-Val-Hyd found after acid hydrolysis of globin at 100 degrees C is about 12 times larger than the sum of N-acetyl-4, 4'-methylenedianiline (AcMDA) and MDA obtained from mild base hydrolysis of hemoglobin. The MDA-Val-Hyd is an isocyanate-specific adduct. MDA and AcMDA released after mild base hydrolyses result most likely from a sulfinamide adduct which is a typical adduct of arylamines. According to these results, higher amounts of isocyanate adducts than arylamine adducts should be expected in workers exposed to isocyanates.
4,4'-亚甲基二苯基二异氰酸酯(MDI)是化学工业中用作中间体的最重要的异氰酸酯。低水平接触MDI后主要的损害类型包括肺部致敏和哮喘。MDI的蛋白质加合物可能参与致敏反应的病因。因此,有必要拥有灵敏且特异的方法来监测工人的异氰酸酯暴露情况。迄今为止,尿液代谢物或蛋白质加合物已被用作接触MDI工人的生物标志物。然而,使用这些方法无法确定生物标志物是由接触MDI还是母体芳香胺4,4'-亚甲基二苯胺(MDA)导致的。这项工作提出了一种定量异氰酸酯特异性血红蛋白加合物的方法。血液蛋白质被用作暴露的标志物,也可能用作疾病发生的靶器官中大分子修饰的剂量大小标志物。为了定量血红蛋白加合物,N(1)-[4-(4-异氰基苄基)phenyl]乙酰胺(AcMDI)与三肽缬氨酰-甘氨酰-甘氨酸和缬氨酸反应,分别生成N-[4-(4-乙酰氨基苄基)phenyl]氨基甲酰基]缬氨酰-甘氨酰-甘氨酸和N-[4-[4-(乙酰氨基苄基)phenyl]氨基甲酰基]缬氨酸。N-[4-[4-(乙酰氨基-3,5-二氘代苄基)-2,6-二氘代苯基]氨基甲酰基]缬氨酸由缬氨酸合成,N(1)-[4-(4-异氰基-3,5-二氘代苄基)-2,6-二氘代苯基]乙酰胺也由缬氨酸合成,用作内标。这些加合物在2 M盐酸中裂解,生成相应的乙内酰脲,分别为3-[4-(4-氨基苄基)phenyl]-5-异丙基-1,3-咪唑啉-2,4-二酮(MDA-Val-Hyd)和3-[4-(4-氨基-3,5-二氘代苄基)-2,6-二氘代苯基]-5-异丙基-1,3-咪唑啉-2,4-二酮。在接触MDI的大鼠珠蛋白中,MDA-Val-Hyd可以剂量依赖的方式被发现。该加合物通过HPLC/MS/MS鉴定,并在用七氟丁酸酐衍生化后通过GC/MS定量。在100℃下珠蛋白酸水解后发现的MDA-Val-Hyd的量比从血红蛋白温和碱水解获得的N-乙酰-4,4'-亚甲基二苯胺(AcMDA)和MDA的总和大约12倍。MDA-Val-Hyd是一种异氰酸酯特异性加合物。温和碱水解后释放的MDA和AcMDA最有可能来自亚磺酰胺加合物,这是芳胺的一种典型加合物。根据这些结果,预计接触异氰酸酯的工人中异氰酸酯加合物的量会高于芳胺加合物。